Results 1 to 10 of about 318,819 (293)
Cytokine release syndrome [PDF]
Journal for ImmunoTherapy of Cancer, 2018 During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell engaging therapies like bispecific T-cell engaging (BiTE) single-chain antibody ...
Alexander Shimabukuro-Vornhagen +8 more
doaj +8 more sources
Rituximab and Cytokine Release Syndrome [PDF]
Case Reports in Oncology, 2012 Rituximab is a biologic agent that is usually well tolerated. With its increasing use for a myriad of rheumatologic and immunologic conditions, post-marketing surveillance has revealed more side effects. Systemic inflammatory response syndrome associated
Hrishikesh S. Kulkarni +1 more
doaj +3 more sources
Cytokine release syndrome after bronchoalveolar lavage
BMC Pulmonary Medicine, 2023 Background Immunosuppressed bone marrow transplant patients with pulmonary infiltrates routinely undergo bronchoscopy with bronchoalveolar lavage (BAL) to investigate potential etiologies.
Margaret Guerriero +3 more
doaj +3 more sources
Journal of Pediatric Critical CareCytokine release syndrome (CRS) is a severe, potentially life-threatening immune-mediated condition characterized by excessive cytokine secretion leading to systemic inflammation and multiorgan dysfunction.
Rachit Mehta, Indira Jayakumar
doaj +3 more sources
Cytokine Release Syndrome: Current Perspectives
ImmunoTargets and Therapy, 2019 Hemant Murthy,1 Madiha Iqbal,1 Julio C Chavez,2 Mohamed A Kharfan-Dabaja1 1Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA; 2Department of Malignant Hematology, Moffitt Cancer Center, Tampa,
Murthy H +3 more
doaj +5 more sources
The Many Faces of Cytokine Release Syndrome-Related Coagulopathy [PDF]
Clinical Hematology International, 2021 Cytokine release syndrome (CRS) has been increasingly recognized in various conditions including the coronavirus disease 2019 (COVID-19). It is not only associated with systemic inflammatory symptoms, but also hematological complications such as ...
Jiasheng Wang, John Doran
doaj +3 more sources
Cytokine release syndrome: grading, modeling, and new therapy [PDF]
Journal of Hematology & Oncology, 2018 Genetically modified T cells that express a chimeric antigen receptor (CAR) are opening a new frontier in cancer immunotherapy. CAR T cells currently are in clinical trials for many cancer types.
Delong Liu, Juanjuan Zhao
doaj +3 more sources
Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy
Diseases, 2022 Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy is an innovative therapeutic option for addressing certain recurrent or refractory hematological malignancies.
Puri Ferreros, Isabel Trapero
doaj +3 more sources
Rituximab induced cytokine release syndrome in an MS patient: A case report
Clinical Case Reports, 2021 Cytokine release syndrome with rituximab has been reported in certain diseases, however, it is rarely reported in MS patients treated with rituximab. The treating physician should suspect the syndrome when typical signs and symptoms appear.
Masoud Etemadifar +4 more
doaj +2 more sources
Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome
European Journal of Case Reports in Internal Medicine, 2020 Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by many factors such as infections. CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis.
Sadettin Uslu
doaj +4 more sources